The Michael J. Fox Foundation (MJFF) has teamed up with H1, a healthcare data company based in New York, to simplify its search for doctors who treat Parkinson's disease patients and gather information about patient populations and treatment methods.
By utilising H1's AI-powered platform called Trial Landscape, which analyses performance data, MJFF aims to connect with healthcare providers, enhance its educational and research initiatives, and gain valuable insights into clinical trial investigators and sites. The foundation also intends to collect data on underrepresented patient groups and the difficulties they encounter, to develop effective strategies for supporting them.
According to Maggie McGuire Kuhl, Vice President of Research Engagement at MJFF, the foundation recognises the importance of partnerships in advancing the development of improved treatments and cures for Parkinson's disease. They chose to collaborate with H1 to expand their network of partners and accelerate breakthroughs in the field.
Nearly one million individuals in the United States live with Parkinson's disease, but clinical trials have historically had low representation from marginalised communities. In April, MJFF sponsored a study published in The Lancet, which revealed a significant breakthrough in Parkinson's disease research — the identification of a biomarker that allows for the detection of the disease before the onset of typical movement symptoms. The biomarker can be detected through a spinal fluid test and offers high diagnostic accuracy.
The foundation expressed optimism about the potential of these findings to enhance care and treatments for individuals living with Parkinson's disease and potentially prevent the progression of symptoms in newly diagnosed patients.
Click here to read the original news story.